Medtronic is showing its strongest top-line growth in a decade, led by cardiovascular and pulsed field ablation momentum. The stock looks like a balanced Buy for moderate-risk investors, though margin pressure and debt keep the turnaround case from being pristine.
Medtronic(MDT) looks like a balanced medium-term Buy for moderate-risk investors because the business is finally showing the kind of broad-based acceleration that large medtech companies often promise and rarely deliver all at once. In FY26, revenue reached $36.364B, up 8.4% reported and 5.8% organic, which management called its strongest annual top-line growth in 10 years. Q4 FY26 added another strong print, with revenue of $9.807B, up 9.9% reported and 6.6% organic, while non-GAAP EPS of $1.55 came in ahead of guidance.
The core of the bull case is not one product. It is a portfolio shift. Cardiovascular grew 10.1% organically in Q4, Cardiac Ablation Solutions rose 78% globally and 124% in the U.S., Medical Surgical grew 5.1% organically, and several newer platforms including Symplicity Spyral, Hugo, Altaviva, and Stealth AXiS are moving from launch story to revenue contributor. That matters because Medtronic has spent years looking like a giant with good assets and sluggish execution. FY26 suggests the machine is starting to turn with more force.
The caution is straightforward. Margin expansion is not yet clean. FY26 non-GAAP operating margin fell 130 bps year over year, tariffs hit Q3 by $93M and were expected to hit FY26 cost of goods sold by about $185M, and the company still carries $28.516B of total debt against $8.965B of cash and equivalents. This is not a pristine balance-sheet compounder. It is a large, cash-generative medtech platform in the middle of an operational upgrade.
That mix leads to a simple conclusion: Medtronic(MDT) is attractive when priced as a slow, mature device company, but less compelling when priced as if the turnaround is already fully harvested. With a trailing P/E of 20.6, forward P/E of 12.1, PEG of 1.29, analyst target of $106.56, and FY27 non-GAAP EPS guidance of $5.90 to $6.00, the stock still offers a reasonable setup if the current growth cadence holds. The medium-term opportunity is real, but it depends on sustained execution in high-growth categories rather than financial engineering.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Medtronic(MDT) is one of the largest diversified medical device companies in the world, with operations across cardiovascular, neuroscience, medical surgical, and diabetes therapies. The company was founded in 1949, is headquartered in Galway, Ireland, employs about 95,000 people, and sells device-based therapies in the U.S., Ireland, and internationally. Its products address more than routine hospital supply needs. They sit inside procedure rooms, operating rooms, cath labs, and chronic-care workflows where physician familiarity, clinical data, and service support matter.
The business model blends capital equipment, implantables, disposables, and software-enabled systems. That is a useful combination. Capital placements can open the door, but recurring procedure-driven consumables and follow-on therapies are where the economics usually improve. Medtronic’s portfolio includes pacemakers, defibrillators, cardiac ablation systems, spinal technologies, neuromodulation devices, surgical stapling and energy tools, patient monitoring, robotic-assisted surgery, and insulin delivery systems.
Scale is one of Medtronic’s defining traits. FY26 revenue reached $36.364B, and the company generated EBITDA of $9.44B. Market capitalization stands near $94.7B. That scale gives Medtronic reach with hospital systems, purchasing organizations, regulators, and physicians. It also gives the company room to absorb weak spots in one franchise while leaning into stronger ones elsewhere. In medtech, that kind of breadth can be a cushion, but it can also become bureaucracy if management loses focus. The recent numbers suggest focus is improving.
Cardiovascular is the company’s largest growth engine right now. In FY26, the segment generated $14.4B of revenue, up 10.8%. In Q4 FY26, segment revenue was $3.797B, up 13.8% reported and 10.1% organic. Management highlighted high-teens growth in Cardiac Rhythm & Heart Failure, low-single-digit growth in Structural Heart & Aortic, and low-single-digit growth in Coronary & Peripheral Vascular. The standout remains Cardiac Ablation Solutions, where revenue rose 78% globally in Q4 and 124% in the U.S.
Neuroscience generated $10.7B in FY26, up 4.8%, and $2.751B in Q4 FY26, up 5.0% reported and 3.0% organic. That is not explosive growth, but it is supported by a broad pipeline. Management called out low-single-digit growth in Neuromodulation, Cranial & Spinal Technologies, and Specialty Therapies. In Q3, Cranial & Spinal Technologies delivered mid-single-digit growth, including 8% growth in Core Spine, and Stealth AXiS received FDA clearance, giving the segment a fresh platform to drive share gains.
Medical Surgical produced $9.4B in FY26, up 5.6%, and $2.388B in Q4 FY26, up 8.0% reported and 5.1% organic. Growth came from low-single-digit gains in Surgical & Endoscopy and low-double-digit growth in Acute Care & Monitoring. In Q3, Endoscopy grew 10% and Acute Care & Monitoring grew 7%, while Surgical grew just 1%. This is a stable but uneven portfolio, and Hugo is the most important swing factor for whether Medical Surgical becomes a growth story rather than a steady utility.
Diabetes is smaller in revenue terms but strategically important because Medtronic plans to separate the business by the end of calendar 2026 through a two-step IPO and split. Q4 FY26 diabetes revenue was $837M, up 15.0% reported and 8.1% organic. FY26 diabetes revenue was $1.8B, up 4.6%. Management said the business saw acceleration in the U.S. driven by Simplera Sync and Instinct, and it also noted that the 780G system is now available through pharmacy with agreements covering the majority of commercially insured lives in the U.S.
The segment picture matters because Medtronic no longer relies on one sleepy franchise to carry the whole company. Cardiovascular is doing the heavy lifting, Medical Surgical is stabilizing, Neuroscience has a credible product cycle, and Diabetes has both growth and strategic optionality through separation. That is a healthier setup than the old version of Medtronic, where the portfolio often looked broad but not especially urgent.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product family to watch is Medtronic’s pulsed field ablation platform, especially Affera and the Sphere-9 catheter. This is where the company is gaining share in one of the most attractive categories in medtech. In Q3 FY26, management said PFA grew nearly 200% worldwide, Cardiac Ablation Solutions grew 80% year over year, and Medtronic gained 4 points of share in a $13B-plus market. By Q4 FY26, Cardiac Ablation Solutions still grew 78% globally and 124% in the U.S., with management citing another 8 points of U.S. share gain.
That kind of growth is not cosmetic. It changes the company’s growth mix. Management said PFA accounted for 80% of CAS revenue in Q3 and described Sphere-9 as a versatile catheter used across persistent and paroxysmal procedures. It also said 50% to 60% of cases now use both PFA and RF energies with the same catheter, which speaks to workflow flexibility. In medtech, workflow wins often matter as much as raw product specs because physicians do not like changing tools unless the new one clearly saves time, improves outcomes, or both.
The pipeline behind the flagship also looks strong. Medtronic received CE Mark for Sphere-360 and initiated the U.S. pivotal trial in Q3 FY26. Management said Sphere-360 is a next-generation single-shot all-in-one PFA and mapping catheter and planned to begin commercialization in Europe in spring 2026. That gives Medtronic a first product, a follow-on product, and a growing installed base. It is a better competitive posture than a one-device story.
Outside PFA, Micra remains a meaningful flagship within Cardiac Rhythm Management. Management cited mid-teens Micra growth in Q4 FY26 and double-digit growth in Q3 FY26. Hugo also deserves flagship status in Medical Surgical because it is strategically important even before it becomes financially large. The U.S. launch has started, first installations and cases have been completed, and procedure volume growth was described as running 2x to 3x the market. That is early-stage evidence, not proof, but it is the kind of evidence that matters.
Medtronic’s competitive advantage comes from a mix of installed base, regulatory muscle, physician relationships, and a pipeline that is finally producing visible commercial wins. The company is not the cheapest operator and not the purest growth stock. Its edge is breadth with enough innovation to keep the breadth from turning stale.
The current innovation stack is unusually broad. Management identified four generational growth drivers in Q3 FY26: the PFA platform for AFib, Symplicity Spyral for hypertension, Altaviva for urge urinary incontinence, and Hugo robotic surgery. Each one targets a large underpenetrated market. Symplicity addresses 18M U.S. patients with uncontrolled hypertension. Altaviva targets a condition affecting 16M people in the U.S. Those are not niche categories.
Stealth AXiS adds another layer. Management said the platform unifies AI-powered planning, robotics, and navigation, and that navigation already drives 70% of U.S. spine procedures. That installed-base fact matters because new platforms sell faster when they fit existing workflow rather than forcing surgeons to relearn the room. Medtronic also said Touch Surgery installations increased more than 20% sequentially in Q3 and surpassed 1,000 systems globally, giving the company a digital ecosystem angle around Hugo.
The company is also using tuck-in M&A to reinforce growth categories. In FY26 it completed the CathWorks acquisition, announced intent to acquire Scientia Vascular and SPR Therapeutics, entered an agreement with Merit Medical Systems for ViaVerte, and invested in Pulnovo Medical. That is not empire building. It looks more like bolt-on reinforcement around cardiovascular, neurovascular, and neuromodulation.
Operationally, Medtronic is improving, but the numbers show a company still working through mix and cost friction. In Q3 FY26, adjusted gross margin was 64.9%, ahead of expectations. Pricing contributed 30 bps, foreign exchange added about 40 bps, and SG&A fell 30 bps as a share of revenue to 32.3%. Those are healthy signs.
The problem is that growth is currently coming from businesses that are not yet margin-maximizing. Management said mix was negative 100 bps in Q3, mostly driven by Cardiac Ablation Solutions and Diabetes. CAS is still in the earlier stage where lower-margin capital placements support later catheter revenue, and Diabetes is in the manufacturing ramp of Simplera. That is the classic medtech launch curve: first the hardware goes out, then the consumables and efficiency catch up. The machine works, but it does not purr on day one.
Tariffs are another real headwind. Management said tariffs hit Q3 by $93M and expected a FY26 COGS impact of about $185M, including $75M in Q4. It also said FY26 gross margin would decrease roughly 30 bps including tariffs. That means some of the margin pressure is external, not operational. Still, investors do not get paid for excuses. They get paid when management offsets them.
There are reasons to think the operating model can improve. Management said pricing, FX, and COGS efficiency programs were expected to more than offset business mix ex tariffs, and it reiterated a commitment to invest in R&D, sales, marketing, and M&A while still driving leverage in functional areas. For a company of this size, disciplined SG&A is often the difference between a good launch cycle and a good stock.
Medtronic operates in large and growing end markets. The global medical devices market is estimated at $681.57B in 2025 and projected to reach $955.49B by 2030, implying a 6.99% CAGR. That is not a speculative market size built on wishful thinking. It is a broad industry with durable demand drivers including aging populations, chronic disease prevalence, minimally invasive procedures, connected care, and AI-enabled devices.
Within that broad market, Medtronic is positioned in several of the most attractive subcategories. PFA in electrophysiology is expanding quickly, and management described it as a $13B-plus market. Symplicity Spyral targets 18M U.S. patients with uncontrolled hypertension. Altaviva targets 16M U.S. patients with urge urinary incontinence. Robotic surgery remains a large strategic market, and spine navigation and robotics continue to evolve toward integrated digital workflows.
The company also benefits from the shift toward more connected and data-driven care. Touch Surgery, remote monitoring, AI-powered planning, and software-enabled device ecosystems fit the direction of the market. This does not mean every digital initiative becomes a profit center. It does mean Medtronic is aligning its product roadmap with where hospital purchasing and physician workflow are headed.
The market backdrop is favorable, but not forgiving. High-growth categories attract intense competition, and reimbursement can lag innovation. That is why Medtronic’s recent share gains in PFA matter more than a generic industry tailwind. A rising tide helps, but in medtech, the boats still need functioning engines.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Medtronic sells primarily to healthcare systems, hospitals, physicians, clinicians, and patients. In practical terms, the key economic customers are hospital systems and procedural specialists. These buyers care about clinical outcomes, ease of use, reimbursement support, training, reliability, and service. Price matters, but workflow disruption can matter more. A device that saves 10 minutes in a busy lab or avoids retraining headaches can win even if it is not the cheapest option.
The customer profile varies by franchise. Cardiovascular products are sold into cath labs, electrophysiology labs, and cardiac rhythm management settings. Neuroscience products go to spine surgeons, neurosurgeons, neurologists, pain specialists, and related procedural teams. Medical Surgical serves operating rooms, endoscopy suites, and acute care environments. Diabetes reaches both clinicians and patients more directly, especially as pharmacy access expands.
Customer stickiness is supported by training and installed base. Management said more than 500 physicians had been trained on Altaviva and that Symplicity added more than 200 new accounts in Q3 FY26. It also said Touch Surgery surpassed 1,000 systems globally. Those are useful signals because adoption in medtech often starts with account activation, training, and workflow integration before it shows up as fully mature revenue.
Medtronic competes against a long list of strong rivals, including Abbott(ABT), Boston Scientific(BSX), Johnson & Johnson(JNJ), Stryker(SYK), Zimmer Biomet(ZBH), Edwards Lifesciences(EW), Dexcom(DXCM), Insulet(PODD), and others depending on the franchise. This is not a market where scale alone guarantees victory. In many categories, Medtronic competes against specialists with sharper focus.
Its advantage is breadth and installed base. In cardiovascular, it has leadership positions in pacing, defibrillation, and ablation. In spine and neuromodulation, it has deep surgeon relationships and navigation assets. In surgical, it can pair instruments, energy, monitoring, and robotics. That breadth can be powerful when hospitals want fewer vendors and more integrated solutions.
The weak point is that breadth can also hide underperformance. Management itself noted competitive pressure in U.S. Structural Heart in Q3 FY26 after annualizing the Evolut FX+ launch. That is a reminder that Medtronic is not winning everywhere. The stock case does not require universal dominance. It requires enough share gains in faster-growing categories to offset the slower or more contested ones.
Right now, the evidence is strongest in PFA and solid in CRM, selected Medical Surgical lines, and parts of Neuroscience. If those areas continue to outperform, Medtronic can grow faster than the market expects from a company of its size. If they stall, the old criticism returns quickly: a very large portfolio with too many moving parts and not enough sharp edges.
Medtronic is less cyclical than many industrial businesses, but it is not insulated from macro forces. Hospitals still manage budgets tightly, reimbursement still shapes adoption curves, and global trade policy can hit device manufacturers through tariffs and supply-chain complexity. Management quantified the tariff issue clearly, with a $93M impact in Q3 FY26 and about $185M expected for FY26 COGS.
China remains another variable. In Q3 FY26, Medtronic reported low-single-digit growth in China while navigating volume-based procurement. Management said that excluding VBP, China growth was mid-single digit. That is a useful distinction because it shows demand was not collapsing, but pricing and procurement pressure were real. In medtech, policy can move margins faster than procedure volumes.
On the positive side, the broader healthcare equipment market still benefits from durable demographic demand. Aging populations, chronic disease, and the push toward less invasive care support procedure volumes over time. Regulatory focus on AI, cybersecurity, and connected devices also favors companies with scale and compliance infrastructure. Medtronic has that infrastructure. Smaller rivals can innovate faster, but they often cannot commercialize globally with the same reach.
Total debt of $28.516B versus $8.965B of cash and equivalents leaves Medtronic with a workable but not pristine balance sheet, especially as tariffs added about $185M to FY26 cost of goods sold.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →FY26 revenue rose to $36.364B, up 8.4% reported and 5.8% organic, but non-GAAP operating margin still fell 130 bps year over year despite the strongest annual top-line growth in 10 years.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →FY27 non-GAAP EPS guidance of $5.90 to $6.00 implies continued earnings growth, supported by analyst expectations that sit near a $106.56 target and a forward P/E of 12.1.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →A trailing P/E of 20.6, PEG of 1.29, and forward P/E of 12.1 suggest Medtronic is no longer cheap on past earnings, but still reasonable if the current growth cadence holds.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework places Medtronic at $103 for fair value, with upside to $106.56 on analyst targets and a stronger case if execution keeps improving in high-growth categories.
Unlock the full analysis
Subscribers get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Medtronic(MDT) is becoming more interesting because the story has shifted from hope to evidence. FY26 revenue growth was the strongest in a decade, Q4 beat on both revenue and EPS, Cardiovascular is gaining real traction, and the pipeline is no longer abstract. Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS all give investors concrete operating markers to follow.
This is still a company that needs to prove it can turn better growth into cleaner margin expansion. Tariffs, launch mix, and debt keep the story grounded. But that is also why the stock remains investable. If Medtronic had already solved every margin issue and fully monetized every new platform, the valuation would almost certainly be less forgiving.
For a moderate-risk investor with a medium-term horizon, Medtronic offers a credible mix of defense and upside. The business has scale, cash flow, and institutional support, but it also has enough product-cycle momentum to break out of the slow-growth label that has weighed on the shares. That combination is rarely glamorous. It can still be profitable.
Medtronic plc (MDT) rises after reporting fiscal Q4 2026 results that showed stronger revenue growth, standout cardiovascular performance, and upbeat FY27 guidance. Investors are responding to a cleaner growth narrative as the medical device giant signals improving momentum and solid cash generation.
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
Medtronic plc (MDT) rises after posting fiscal Q4 and full-year FY2026 results that beat guidance and showed its strongest annual revenue growth in a decade. The company also raised its dividend and issued upbeat FY2027 guidance, helping investors reprice the stock as a faster-growing medtech name.